About FDA

Bioinformatics and Biostatistics

Weida Tong, Ph.D.
Meet the Division Director:  Weida Tong, Ph.D.

Dr. Tong's career has been dedicated to leadership in developing and applying bioinformatics, chemoinformatics, and computational methods in the areas of systems biology, predictive toxicology, and clinical application. He serves as a Science Advisory Board(SAB) member for several large initiatives involving multiple institutes within Europe and the U.S. He also holds several adjunct positions at U.S. universities. His division at FDA’s National Center for Toxicological Research spans, IT, software development, biostatistics, as well as bioinformatics research focusing on methodologies and standards to advance a diversity of areas in regulatory science and precision medicine. Some particularly visible research areas currently are: (1) the Microarray/Sequencing Quality Control (MAQC/SEQC) consortium to develop standard analyses protocols and quality control metrics for emerging technologies for regulatory science and precision medicine applications; (2) further development of the Liver Toxicity Knowledge Base (LTKB) for drug safety evaluation; (3) in silico drug repositioning for the enhanced treatment of rare or orphaned diseases; and, (4) development of the FDA bioinformatics system, ArrayTrackTM suite, software used for FDA review and research in pharmacogenomics. In addition, the division also specializes in molecular modeling and QSARs, with current activities involving estrogen, androgen, and endocrine active compound screening. His research (>200 publications) is cataloged in prominent peer-reviewed journals. 

The Division of Bioinformatics and Biostatistics develops integrated bioinformatics and biostatistics capability to address increasing needs in biomarker development, drug safety, drug repositioning, personalized medicine, and risk assessment. 

The Division is comprised of four branches:

  • Bioinformatics—research efforts focused on predictive toxicology, precision medicine, biomarker development, drug safety, and drug repositioning. Most research projects are in collaboration with scientists within NCTR, across FDA Product Centers, and in the larger scientific community. One of the key endeavors is to construct knowledge bases in the specific areas of FDA’s responsibility to provide a data-driven decision-making environment for enhanced safety evaluation and precision medicine.   
     
  • Biostatistics—conducts peer-reviewed research of statistical methods to analyze toxicological and molecular data as well as data-mining techniques for pattern identification and signal detection. The branch also provides statistical support related to FDA’s mission to protect and promote public health. 
     
  • Scientific Computing—provides critical support and enhancement to infrastructure in the areas of software and database development for research support and research management, high performance computing, systems integration, and information system asset management and procurement.
     
  • R2R (review-to-research and return)—strengthens the division, focuses on “knowledge uptake” of the Division’s research products for regulatory application, and enables “data liberation” of regulatory data from the FDA Product Centers. Thus, facilitating regulatory-science research in the Division and increasing NCTR's linkages with FDA Product Centers.

Back to Top of Page

NCTR Bioinformatic Tools

Contact Information

For more information, please contact Weida Tong, Ph.D. at 870-543-7142 or weida.tong@fda.hhs.gov.

Back to Top of Page

Resources for You

Page Last Updated: 11/14/2018
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English